Sangamo Therapeutics (NASDAQ:SGMO) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Friday.
According to Zacks, “Sangamo Therapeutics, Inc. is a biotechnology company. It focuses on research and development of genomic therapies as well as develops medicines for patient with genetic diseases. The Company’s product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. Sangamo Therapeutics Inc., formerly known as Sangamo BioSciences Inc., is based in Richmond, United States. “
Other equities analysts also recently issued research reports about the company. Piper Jaffray Companies set a $25.00 target price on Sangamo Therapeutics and gave the company a “buy” rating in a research report on Wednesday. BidaskClub raised Sangamo Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, December 29th. Jefferies Group reaffirmed a “buy” rating and issued a $18.00 target price on shares of Sangamo Therapeutics in a research report on Friday, October 13th. Wedbush reaffirmed a “hold” rating and issued a $6.00 target price on shares of Sangamo Therapeutics in a research report on Wednesday, November 15th. Finally, Barclays started coverage on Sangamo Therapeutics in a research report on Wednesday, November 22nd. They issued an “overweight” rating and a $20.00 target price on the stock. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Sangamo Therapeutics currently has an average rating of “Buy” and a consensus price target of $18.83.
Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.04. The firm had revenue of $11.81 million for the quarter, compared to the consensus estimate of $10.37 million. Sangamo Therapeutics had a negative return on equity of 31.81% and a negative net margin of 157.66%. The business’s revenue was up 333.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.27) earnings per share. equities analysts forecast that Sangamo Therapeutics will post -0.73 EPS for the current year.
In related news, Director Saira Ramasastry sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, November 17th. The stock was sold at an average price of $14.67, for a total value of $73,350.00. Following the completion of the sale, the director now directly owns 5,000 shares in the company, valued at $73,350. The sale was disclosed in a filing with the SEC, which is available at this link. Also, VP Curt A. Herberts III sold 11,803 shares of the business’s stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $18.00, for a total value of $212,454.00. Following the completion of the sale, the vice president now owns 27,636 shares of the company’s stock, valued at $497,448. The disclosure for this sale can be found here. Insiders sold 53,433 shares of company stock worth $894,146 in the last ninety days. 5.50% of the stock is owned by company insiders.
Hedge funds have recently modified their holdings of the stock. Blair William & Co. IL boosted its stake in shares of Sangamo Therapeutics by 4.3% in the second quarter. Blair William & Co. IL now owns 12,100 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 500 shares during the period. Aperio Group LLC bought a new stake in Sangamo Therapeutics during the second quarter worth $108,000. Principal Financial Group Inc. lifted its stake in Sangamo Therapeutics by 6.8% during the second quarter. Principal Financial Group Inc. now owns 12,978 shares of the biopharmaceutical company’s stock worth $114,000 after purchasing an additional 832 shares during the last quarter. Quantbot Technologies LP bought a new stake in Sangamo Therapeutics during the third quarter worth $118,000. Finally, Virtu KCG Holdings LLC bought a new stake in Sangamo Therapeutics during the second quarter worth $124,000. Institutional investors and hedge funds own 64.33% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This story was reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.chaffeybreeze.com/2018/01/05/sangamo-therapeutics-sgmo-lowered-to-hold-at-zacks-investment-research.html.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.